Clinical and Commercial Manufacturing
We provide our clients with a broad range of adherent and suspension-based viral vector and vaccine manufacturing services. Our cGMP facilities offer scalability up to 2000L and the reliability of platform processes and quality systems.
LEARN MORE
Process Development
We use a set of rigorous process development guidelines for process characterization, DoE and QbD principles to establish, implement and improve our clients’ viral vector and vaccine manufacturing processes.
LEARN MORE
Viral Vector R&D Production
We manufacture research and toxicology grade viral vectors that support preclinical studies, which include pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies.
LEARN MORE
Plasmid Manufacturing
We manufacture research and toxicology grade plasmids, which support pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies. In 2022, we will be offering Phase I/IIa plasmid manufacturing services.
LEARN MORE
We support clients through all phases of development and commercialization.
Stay connected with Andelyn Biosciences.
Our Name
The name “Andelyn” was chosen to pay tribute to two brave young patients that participated in pivotal clinical trials that make today’s gene therapies possible.
Updates from Andelyn
News
May 23, 2024
Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)
COLUMBUS, OH, May 23, 2024 – Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and...
News
March 25, 2024
Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency
COLUMBUS, OH, March 25, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...
News
February 28, 2024
Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)
COLUMBUS, OH, February 28, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...
News & Media
February 23, 2024
Andelyn Biosciences Announces New Chief Operations Officer
(COLUMBUS, Ohio) – Andelyn Biosciences announces the promotion and appointment of Cyrill Kellerhals as Chief Operations Officer (COO). Cyrill will lead...
Our Employees Fuel Our Success
Andelyn is made up of an Inspired, Innovative and Compassionate team that contribute towards a rich company culture. We are always looking for great people who want to do great things.